University of Chicago: Prostatic Neoplasms trials

The registry lists 27 Prostatic Neoplasms studies with University of Chicago as lead sponsor. 9 are open to participants now and 8 have results posted.

Phase 1 7Phase 2 9Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• PSMA PET for Surveillance After Focal TherapyRecruitingNCT07115914Not applicable
• Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly PatientsRecruitingNCT06824818Not applicable
• Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)RecruitingNCT06705803
• Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.Not yet recruitingNCT06660862Phase 4
• Geriatric Assessment and Technology Evaluation in Prostate CancerRecruitingNCT06215508
• Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of LifeRecruitingNCT06171269Not applicable
• Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate AblationRecruitingNCT05790213Phase 2
• A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate CancerRecruitingNCT05726292Phase 2
• MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted BiopsyRecruitingNCT05710380Not applicable
• Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer BiopsyCompletedNCT03585660Not applicableResults posted
• Rucaparib and Nivolumab in Patients With Prostate or Endometrial CancerTerminatedNCT03572478Phase 1/2Results posted
• Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate CancerCompletedNCT02012296Phase 1/2Results posted
• MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate CancerCompletedNCT01792024Not applicableResults posted
• Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate CancerCompletedNCT01599793Phase 2Results posted
• Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate CancerCompletedNCT01543776Phase 2Results posted
• Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate CancerActive, not recruitingNCT01342367Not applicableResults posted
• Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate CancerTerminatedNCT00515112Phase 2Results posted
• A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer PatientsTerminatedNCT05679388Phase 1
• Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.TerminatedNCT05276492Phase 1
• Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone TreatmentsCompletedNCT04705038Not applicable
• Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate CancerCompletedNCT03674814Phase 1
• Laser Based Focal Ablation of Low Grade Prostate CancerCompletedNCT01192438Not applicable
• A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate CancerCompletedNCT01187485Phase 1
• Prostate Cancer Utilities and Cost-Effectiveness AnalysisCompletedNCT00203918
• SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate CancerCompletedNCT00026377Phase 1
• Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00015977Phase 2
• SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00006002Phase 2